

Rwanda Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

| 1. Country: Rwanda | | | | | | | | | | | | | | | | |
|--|-------------|--|--------------------|-----------------------|-------------------------|------------------------------------|---------|------------------------------------|-----|-------|------------------------|--|-------|---|-------|-------|
| 2. Grant number: 18-RWA-32a-A,19-RWA-32a-A | | | | | | | | | | | | | | | | |
| 3. Date of Decision Letter: 5 March 2019 | | | | | | | | | | | | | | | | |
| 4. Date of the Partnership Framework Agreement: 7 June 2013 | | | | | | | | | | | | | | | | |
| 5. Programme title: Injection safety devices ¹ | | | | | | | | | | | | | | | | |
| 6. Programme duration²: 2018-2019 | | | | | | | | | | | | | | | | |
| 7. Programme Budget (indicative)³: (subject to the terms of the partnership framework agreement, if applicable) | | | | | | | | | | | | | | | | |
| <table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 15%;">2018</th> <th style="width: 15%;">2019</th> <th style="width: 15%;">Total³</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Programme Budget (US\$)</td> <td style="text-align: center; padding: 2px;">1,500</td> <td style="text-align: center; padding: 2px;">5,500</td> <td style="text-align: center; padding: 2px;">7,000</td> </tr> </tbody> </table> | | 2018 | 2019 | Total ³ | Programme Budget (US\$) | 1,500 | 5,500 | 7,000 | | | | | | | | |
| | 2018 | 2019 | Total ³ | | | | | | | | | | | | | |
| Programme Budget (US\$) | 1,500 | 5,500 | 7,000 | | | | | | | | | | | | | |
| 8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ | | | | | | | | | | | | | | | | |
| <table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;">TOTAL injection safety devices to be purchased with Gavi funds in each year</th> <th style="width: 20%;">2018</th> <th style="width: 20%;">2019</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Number of AD syringes</td> <td></td> <td style="text-align: center; padding: 2px;">101,300</td> </tr> <tr> <td style="padding: 2px;">Number of re-constitution syringes</td> <td></td> <td style="text-align: center; padding: 2px;">3,700</td> </tr> <tr> <td style="padding: 2px;">Number of safety boxes</td> <td></td> <td style="text-align: center; padding: 2px;">1,225</td> </tr> <tr> <td style="padding: 2px;">Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</td> <td style="text-align: center; padding: 2px;">1,500</td> <td style="text-align: center; padding: 2px;">5,500</td> </tr> </tbody> </table> | | TOTAL injection safety devices to be purchased with Gavi funds in each year | 2018 | 2019 | Number of AD syringes | | 101,300 | Number of re-constitution syringes | | 3,700 | Number of safety boxes | | 1,225 | Annual Amounts for injection safety devices for all Gavi vaccines (US\$) | 1,500 | 5,500 |
| TOTAL injection safety devices to be purchased with Gavi funds in each year | 2018 | 2019 | | | | | | | | | | | | | | |
| Number of AD syringes | | 101,300 | | | | | | | | | | | | | | |
| Number of re-constitution syringes | | 3,700 | | | | | | | | | | | | | | |
| Number of safety boxes | | 1,225 | | | | | | | | | | | | | | |
| Annual Amounts for injection safety devices for all Gavi vaccines (US\$) | 1,500 | 5,500 | | | | | | | | | | | | | | |
| Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u> | | | | | | | | | | | | | | | | |
| <table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID</th> <th style="width: 30%;">2019</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Number of AD syringes</td> <td style="text-align: center; padding: 2px;">12,100</td> </tr> <tr> <td style="padding: 2px;">Number of re-constitution syringes</td> <td style="text-align: center; padding: 2px;">-</td> </tr> <tr> <td style="padding: 2px;">Number of safety boxes</td> <td style="text-align: center; padding: 2px;">150</td> </tr> </tbody> </table> | | New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID | 2019 | Number of AD syringes | 12,100 | Number of re-constitution syringes | - | Number of safety boxes | 150 | | | | | | | |
| New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID | 2019 | | | | | | | | | | | | | | | |
| Number of AD syringes | 12,100 | | | | | | | | | | | | | | | |
| Number of re-constitution syringes | - | | | | | | | | | | | | | | | |
| Number of safety boxes | 150 | | | | | | | | | | | | | | | |

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

| | | |
|---|-------------|--|
| Annual Amounts for injection safety devices for Vaccine (US\$) | 1,000 | |
| New Vaccine Support (NVS), Measles Rubella, 10 dose(s) per vial, LYOPHILISED | 2019 | |
| Number of AD syringes | 23,800 | |
| Number of re-constitution syringes | 3,700 | |
| Number of safety boxes | 325 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 1,500 | |
| New Vaccine Support (NVS), Pneumococcal (PCV13), 4 dose(s) per vial, LIQUID | 2019 | |
| Number of AD syringes | 32,500 | |
| Number of re-constitution syringes | - | |
| Number of safety boxes | 375 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 1,500 | |
| New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID | 2019 | |
| Number of AD syringes | 32,900 | |
| Number of re-constitution syringes | - | |
| Number of safety boxes | 375 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 1,500 | |
| 9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | |
| 10. Self-procurement: N/A | | |
| 11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter. | | |

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

5 March 2019